Currently, many clinical trials are being conducted for c-Met targeting in HCC management, using c-Met inhibitors such as INC280, foretinib, MSC2156119J, golvatinib, tivantinib, and cabozantinib [12]. The gene discussed is MET; the disease is hepatocellular carcinoma.